HomeCompareBMNDF vs JNJ

BMNDF vs JNJ: Dividend Comparison 2026

BMNDF yields 18181.82% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BMNDF wins by $658834.83M in total portfolio value
10 years
BMNDF
BMNDF
● Live price
18181.82%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$658834.86M
Annual income
$54,543,841,013.90
Full BMNDF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — BMNDF vs JNJ

📍 BMNDF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBMNDFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BMNDF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BMNDF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BMNDF
Annual income on $10K today (after 15% tax)
$1,545,454.55/yr
After 10yr DRIP, annual income (after tax)
$46,362,264,861.82/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, BMNDF beats the other by $46,362,260,875.83/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BMNDF + JNJ for your $10,000?

BMNDF: 50%JNJ: 50%
100% JNJ50/50100% BMNDF
Portfolio after 10yr
$329417.45M
Annual income
$27,271,922,851.65/yr
Blended yield
8.28%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

BMNDF
No analyst data
Altman Z
-414.3
Piotroski
1/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BMNDF buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBMNDFJNJ
Forward yield18181.82%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%28%
Portfolio after 10y$658834.86M$30.3K
Annual income after 10y$54,543,841,013.90$4,689.40
Total dividends collected$553757.55M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: BMNDF vs JNJ ($10,000, DRIP)

YearBMNDF PortfolioBMNDF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$919,791$909,090.91$10,592$272.30+$909.2KBMNDF
2$40,057,707$39,073,530.55$11,289$357.73+$40.05MBMNDF
3$838,042,485$795,180,738.70$12,123$472.89+$838.03MBMNDF
4$8,670,481,609$7,773,776,150.53$13,141$629.86+$8670.47MBMNDF
5$46,860,761,379$37,583,346,056.88$14,408$846.81+$46860.75MBMNDF
6$145,058,842,015$94,917,827,338.98$16,021$1,151.60+$145058.83MBMNDF
7$292,512,437,337$137,299,476,380.97$18,122$1,588.22+$292512.42MBMNDF
8$442,364,760,258$129,376,452,307.77$20,930$2,228.20+$442364.74MBMNDF
9$564,757,963,223$91,427,669,747.44$24,792$3,191.91+$564757.94MBMNDF
10$658,834,861,663$54,543,841,013.90$30,274$4,689.40+$658834.83MBMNDF

BMNDF vs JNJ: Complete Analysis 2026

BMNDFStock

Biomind Labs Inc., a biotech research and development company, focuses on developing novel pharmaceutical drugs and nanotech delivery systems for various psychiatric and neurological conditions. The company is developing BMND01, which is in Phase II clinical trials for use in the treatment of depression; and BMND08, a 5-Methoxy-N,N-dimethyltryptamine based candidate that is in Phase II clinical trials for treatment of depression and anxiety in patients with Alzheimer's-type cognitive impairment. It is also developing new and preclinical drug candidates, including BMND02 for treating fibromyalgia, BMND03 for treating addictive disorders, BMND05 for treating chronic pain, BMND06 for treating inflammation, and BMND07 for treating major depressive disorder. The company is headquartered in Canelones, Uruguay.

Full BMNDF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this BMNDF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BMNDF vs SCHDBMNDF vs JEPIBMNDF vs OBMNDF vs KOBMNDF vs MAINBMNDF vs ABBVBMNDF vs MRKBMNDF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.